Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

GAR Helps Counter Legal Pitfalls of Cancer Screening, Diagnosis

June 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

WASHINGTON--Put GAR in your patients' records. It can prove extremely useful should you find yourself being sued for medical malpractice, Marvin A. Dewar, MD, JD, said at the National Conference on Prevention and Early Detection, sponsored by the American Cancer Society.

WASHINGTON--Put GAR in your patients' records. It can prove extremelyuseful should you find yourself being sued for medical malpractice,Marvin A. Dewar, MD, JD, said at the National Conference on Preventionand Early Detection, sponsored by the American Cancer Society.

GAR is an acronym for "general information, alternatives,risks"--three key points every physicians needs to discusswith patients before cancer screening or diagnosis,

Dr. Dewar, director, Family Practice Residency Program, the Universityof Florida College of Medicine, Gainesville, said that malpracticecases alleging that a physician delayed diagnosis or failed todiagnose a cancer continue to increase.

In a 1991 Florida study, Dr. Dewar and his colleagues found thatin cases involving primary care physicians, failure to diagnosecancer was the most common allegation, representing 16% of allpaid claims, at an average cost of $160,352. Failure to diagnosebreast cancer ranked first, followed by lung, prostate, and coloncancer.

One element in defending against such lawsuits is having and documentinga good informed consent process. And thus, he recommends rememberingGAR.

"Informed consent is a conversation that you as providershave with patients," Dr. Dewar said. "It is the understanding,the meeting of the minds between the patient and the provider.The documentation of the informed consent is not informed consent,but it is important from the legal protection standpoint."

He urged that physicians give each patient general information,explain the alternatives, describe the risks, and note this inthe patient's record.

"A plastic surgeon or a breast surgeon will dictate voluminousand detailed informed consent," Dr. Dewar said. "Atthe cancer detection level, you and I often don't have time todo that. Nonetheless, documentation is important, and I suggestthat you do it."

Impact of Practice Guidelines

Clinical practice guidelines have been the subject of much debateabout whether they increase the risk of malpractice litigationor protect providers and decrease the threat. In fact, such guidelinescan prove to be a mixed blessing. The most helpful practice guidelinesfor physicians, Dr. Dewar commented, are those that are widelyaccepted by the medical community.

In areas where guidelines diverge or conflict, practice recommendations"are not going to carry very much legal weight," hesaid, "because they will be just as confusing to the juryas they are to many providers and patients."

More relevant to malpractice suits are guidelines developed specificallyto address situations that commonly lead to litigation. But mostimportant, practice guidelines "have to be straightforwardand readily interpreted in the litigation setting," Dr. Dewarsaid.

For example, he said, the American Cancer Society's guidelinesfor screening intervals are very simple, clear, and easily understood."They will have more weight in a litigation setting thanwill more lengthy and confusing guidelines."

Defining Medical Negligence

Legally, to succeed in winning compensation in a malpractice suit,a patient must prove medical negligence, and this essentiallyconsists of four points.

First, an obligation must exist that the provider give a certainlevel of care; second, that duty must be breached; third, thatbreach must cause harm to the patient; and fourth, that harm mustinflict legally recognizable damage, such as loss of wages, onthe patient.

Originally, local medical standards served as the criteria fordetermining a physician's standard of care; now physicians facea national standard. "Although the resources may be different,the standard of care that you provide with those resources isgoing to be the same in Wisconsin as it is in Atlanta," Dr.Dewar commented.

However, physicians do have what attorneys call the "respectableminority rule" on their side. This is especially importantin such areas as prostate screening that are marked by scientificcontroversy and varying recommendations and practice guidelines.

"If the care decision that you go by is supported by whatwe call a respectable minority of the medical profession, then,in fact, you have not breached the duty of care," Dr. Dewarsaid. "So in an area where there is tremendous scientificdebate, the clinician is not going to be put on the hook, theoretically,for following one of the viable options."

However, where one practices can make a difference in the criteriafor proving harm, legally referred to as "causation."Most states use "the 51% rule," Dr. Dewar said, whichmeans that "the breach of duty had to be the probable causeof the injury, with a 51% chance that the failure to do something,or the doing of something that shouldn't have been done, led tothe injury."

A minority of states, including Illinois and West Virginia, usea more stringent rule, such as the physician's action resultingin "some loss of chance of a better outcome," and theserules work more to the plaintiff's advantage," he said.

The large majority of medical malpractice suits never stay thefull legal course from accusation to jury verdict, he said. Nationally,73% of medical malpractice cases end in settlement, with another10% dismissed by the courts.

One of physicians' greatest malpractice fears--the awarding ofpunitive damages--is actually quite rare in the health-care setting,Dr. Dewar said, since they require proof of willful and wantonnegligent conduct.

Articles in this issue

Psychosocial Oncology May Benefit From System Reform
Know Your Partners, Know Your Goals in Joint Ventures Between Hospitals and Universities
Managed Care Reform: Wait Until Next Year for House, Senate
Converting Quality of Life Data to 'Q' Scores Allows Comparisons
Shorter Paclitaxel Infusions Add to Neuropathy Risk
Breast Cancer Mortality Rates Down
Pain Scale Resembling Thermometer May Be Easier to Use Than VAS
Immediate Hormone Therapy Improves Prostate Cancer Survival
New Test for Prostate Cancer Risk
Topotecan: Significant Activity in Ovarian Cancer
Prostate Cancer Guideline Classifies Patients By Risk Status
New Monograph Describes Racial/Ethnic Cancer Patterns in the US
Moral Challenges Ahead as Managed Care Marches On
One Doctor Tells His Experience With Hospital Mergers
BRCA2 Gene Mutations Linked to Ovarian Cancer Cases
Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content
Advertisement

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable with prior reports of each individual agent.

Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer

Russ Conroy
November 6th 2025
Article

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable with prior reports of each individual agent.


Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.


The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

UGN-103 Exhibits Durable Responses in Recurrent LG-IR-NMIBC

Roman Fabbricatore
November 6th 2025
Article

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.

Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment

Roman Fabbricatore
November 5th 2025
Article

Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.


How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Ariana Pelosci
November 5th 2025
Article

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Related Content
Advertisement

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable with prior reports of each individual agent.

Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer

Russ Conroy
November 6th 2025
Article

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable with prior reports of each individual agent.


Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.


The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

UGN-103 Exhibits Durable Responses in Recurrent LG-IR-NMIBC

Roman Fabbricatore
November 6th 2025
Article

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.

Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment

Roman Fabbricatore
November 5th 2025
Article

Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.


How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Ariana Pelosci
November 5th 2025
Article

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.